Effects of OCTA-guided PDT in Acute CSC

Central Serous Chorioretinopathy Clinical Trial

Official title:

Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03497000
• Other study ID #: Peking UPH
• Status: Completed
• Phase: N/A
• First received: March 28, 2018
• Last updated: April 14, 2018
• Start date: September 1, 2017
• Est. completion date: March 27, 2018

Study information

• Verified date: April 2018
• Source: Peking University People's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

OCTA-guided PDT is as safe and effective as ICGA-guided PDT in the treatment of acute central serous chorioretinopathy. Or OCTA-guided PDT is more effective than ICGA-guided PDT in the treatment of acute central serous chorioretinopathy, safe as well.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: March 27, 2018
• Est. primary completion date: December 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Idiopathic detachment of the neurosensory retina with a focal leak at the level of the RPE with FA

• Presence of SRF and/or serous pigment epithelial detachment on OCT

• Presence of abnormal dilated choroidal vasculature in ICGA

Exclusion Criteria:

• Patients with other ocular conditions commonly associated with SRF, such as choroidal neovascularization, polypoidal choroidal vasculopathy (PCV), diabetic retinopathy, retinal vascular occlusion, Coat's disease

• Any disease that may affect the quality of imaging (quality of OCTA images < 6), such as cataract, high myopia or nystagmus

• History of ocular surgeries including retinal laser

• Pregnancy

• Any uncontrolled systemic disease

• Any condition rendering patients intolerable to image acquisition

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy
• Tomography, Optical Coherence

Intervention

Procedure:
• OCTA-guided Photodynamic therapy
Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
• ICGA-guided Photodynamic therapy
Half-dose photodynamic therapy using verteporfin under the guidance of ICGA

Locations

Country	Name	City	State
China	People's Hospital of Peking University	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Peking University People's Hospital	National Natural Science Foundation of China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with subretinal fluid resolution on OCT after PDT of two groups		3 months
Secondary	Number of patients with leakage point resolution on FFA after PDT of two groups		3 months
Secondary	Number of recurrent CSC after PDT of two groups		3 months
Secondary	BCVA (best corrected visual acuity) at every follow-up of two groups		1 month, 3 months